Regenxbio (NASDAQ: RGNX) reported Q2 EPS of $0.43, $0.18 better than the analyst estimate of $0.25. Revenue for the quarter came in at $108.02 million versus the consensus estimate of $113.74 million.

For earnings history and earnings-related data on Regenxbio (RGNX) click here.